Not Just Another Index.
It’s The New Generation.®
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
New: The IPOX® High Dividend 7% Strategy
An Innovative Index Strategy
combining Income & Growth!
Upcoming Global IPOs
The IPOX® Newsletters
IPO News
Global IPO activity is high, especially in the US with Klarna's potential $15B IPO. Asia-Pacific is highlighted by JX Advanced Metal's potential record $3B Japan IPO and Mixue's $500M HK listing. Europe sees Novo Banco's €5B IPO and London vying for listings like IVC Evidensia and CurrentBody.
Robust global IPO activity across multiple sectors: Significant US listings include SailPoint, projecting an $11.5B valuation, and DailyPay, targeting $3-4B. Honeywell's planned spin-offs represent a notable corporate restructuring. European markets are active, featuring Novo Banco and CurrentBody. In Asia, MMC Port's anticipated $1.34B Malaysian IPO highlights the region's strength. The Middle East maintains a positive outlook, with Saudi Arabia driving deal flow.
Large potential IPOs are emerging across regions. In the US, Silvus considers a $5B valuation IPO, while Histosonics aims for a multi-billion dollar valuation. SailPoint eyes a $1B Nasdaq return. Europe sees EcoCeres planning a $5B IPO and HBX Group with strong book coverage for its Amsterdam listing.
IPOX® in the News
IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.
IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.
IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.
IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.
IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.